Heroin anticraving medications: A systematic review

REFERENCES

• Zijlstra F, Booij J, Brink W, Franken IH. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol 2008; 18:262–270.
   PubMed Web of Science ®Google Scholar
• Sell LA, Morris JS, Bearn J, Frackowiak RSJ, Friston KJ, Dolan RJ. Neural responses associated with cue evoked emotional states and heroin in opiate addicts. Drug Alcohol Depend 2000; 60:207–216.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Lee T, Zhang J, Wu Q, Wu R, Weng X, Hu X. Thirsty heroin addicts show different fMRI activations when exposed to water-related and drug-related cues. Drug Alcohol Depend 2006; 83:157–162.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao L, Epstein D, Zhang X, Lu L. Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers. Pharmacol Biochem Behav 2007; 87:141–145.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao L, Copersino M, Fang Y, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 2008; 579:160–166.
   PubMed Web of Science ®Google Scholar
• Sinha R, Catapano D, O'Malley S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology 1999; 142:343–351.
   PubMed Web of Science ®Google Scholar
• Sinha R, Fuse T, Aubin LR, O'Malley S. Psychological, stress drug-related cues and cocaine craving. Psychopharmacology 2000; 152:140–148.
   PubMed Web of Science ®Google Scholar
• Langleben D, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, O'Brien C, Childress A. Acute effect of methadone maintenance dose on brain fMRI response to heroin-related cues. Am J Psychiatry 2008 Mar; 165:3.
   Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Stout S, Casarella, J, Amar R, Smith-Cox J, Drexler K. Effect of methadone maintenance treatment on heroin craving, a literature review. Journal of addictive diseases (in press).
   Google Scholar
• Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA 1965; 193:80–84.
   Web of Science ®Google Scholar
• Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966; 66:2011–2017.
   PubMedGoogle Scholar
• Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract 2009 May; 15(3):227–234.
   PubMed Web of Science ®Google Scholar
• Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Methadone maintenance dosing guidelines for opioid dependence, a literature review. J Addict Dis 2010; 29(1):1–14.
   PubMed Web of Science ®Google Scholar
• Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services and Outcome. New York: Springer-Verlag, 1991.
   Google Scholar
• Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, Johnson RE. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: A randomized clinical trial. JAMA 1997; 277:1945–1951.
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A Veterans Administration cooperative study. Arch Gen Psychiatry 1976; 33:709–720.
   PubMed Web of Science ®Google Scholar
• Fareed A, Roberts M, Sleboda M, Casarella J, Amar R, Drexler K. High dose versus moderate dose methadone maintenance, is there a better outcome. J Addict Dis 2009; 28(4):399–405.
   PubMed Web of Science ®Google Scholar
• Farré M, Mas A, Torrens M, Moreno V, Camí J. Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug Alcohol Depend. 2002 Feb 1; 65(3):283–290.
   PubMed Web of Science ®Google Scholar
• Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. Am J Public Health 1995 Jan; 85(1):83–88.
   PubMed Web of Science ®Google Scholar
• Shi J, Liu T, Wang X, Epstein D, Zhao L, Zhang X, Lu L, Tetrodotoxin reduces cue-induced drug craving and anxiety in abstinent heroin addicts. Pharmacol Biochem Behav 2009; 92:603–607.
   PubMed Web of Science ®Google Scholar
• Shi J, Jun W, Zhao L, Xue Y, Zhang X, Kosten T, Lu L, Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts. Eur J Pharmacol 2009; 615:108–112.
   PubMedGoogle Scholar
• White J, Bell J, Saunders J, Williamson P, Makowska M, Farquharson A, Beebe K, Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009; 103:37–43.
   PubMed Web of Science ®Google Scholar
• Hyman S, Fox H, Hong K, Doebrick C, Sinha R, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol 2007; 15(2):134–143.
   PubMed Web of Science ®Google Scholar
• Dijkstra B, De Jong C, Bluschke S, Krabbe P, van der Staak CP. Does naltrexone affect craving in abstinent opioid dependent patients? Addict Biol 2007; 12:176–182.
   PubMed Web of Science ®Google Scholar
• Comer S, Sullivan M. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007; 193:235–245.
   PubMed Web of Science ®Google Scholar
• Franken I, Hendriks V, Stam C, Brink W. A role for dopamine in the processing of drug cues in heroin dependent patients. Eur Neuropsychopharmacol 2004; 14:503–508.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 2003; 349(10):949–958.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Schuh K, Hopper J, Schuster C, Johanson C. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 2002; 160:344–352.
   PubMed Web of Science ®Google Scholar
• Comer S, Collins E, Fischman MW. Buprenorphine sublingual tablets: Effects on IV heroin self-administration by humans. Psychopharmacology 2001; 154:28–37.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Johanson C, Schuster C. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999; 56:191–203.
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra C, Collins J, Batki S, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998; 93(4):475–486.
   PubMed Web of Science ®Google Scholar
• Cowan A. Buprenorphine: The basic pharmacology revisited. J Addict Med 2007 Jun; 1(2):68–72.
   PubMed Web of Science ®Google Scholar
• O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin dependent patients. Ann Intern Med 2000; 133(1):40–54.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, O'Connor PG. Office-based treatment of opioid dependent patients. N Engl J Med 2002: 347(11):339–345.
   PubMedGoogle Scholar
• Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: Reaching newpatient populations. Am J Psychiatry 2001; 158:1200–1204.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol 2005; 13:293–302.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and METH for opioid dependence. N Engl J Med 2000; 343:1290–1297.
   PubMed Web of Science ®Google Scholar
• Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and METH maintenance in opiate addicts. Eur Addict Res 1998; 4(Supplement 1):3–7.
   PubMedGoogle Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996; 16:58–67.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson D. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug Alcohol Depend 2003; 70:S49–S57.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181:358–364.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401–407.
   PubMed Web of Science ®Google Scholar
• Mello NK, Bree MP, Mendelson JH. Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther 1983; 225:378–386.
   PubMed Web of Science ®Google Scholar
• Mendelson JH, Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151:1025–1030.
   PubMedGoogle Scholar
• Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713–720.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmacology (Berl) 1994a; 116:401–406.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994b; 151(7):1025–1030.
   PubMed Web of Science ®Google Scholar
• Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in treatment of opioid dependence. Swiss multicenter study. Eur Addict Res 1998; 4(Supplement 1):13–18.
   PubMedGoogle Scholar
• Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 1996; 53:401–407.
   PubMed Web of Science ®Google Scholar
• Mattick R, Ali R, White J, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients, Addiction 2003; 98:441–452.
   PubMed Web of Science ®Google Scholar
• Greenwald M. heroin craving and drug use in opioid-maintained volunteers: Effects of methadone dose variations. Exp Clin Psychopharmacol 2002; 10(1):39–46.
   PubMed Web of Science ®Google Scholar
• Ilgen M, Jain A, Kim H, Trafton J. The effect of stress on craving for methadone depends on the timing of last methadone dose. Behav Res Ther 2008; 46:1170–1175.
   PubMed Web of Science ®Google Scholar
• Childress AR, McLellan AT, O'Brien CP. Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. J Subst Abuse Treat 1986; 3:173–179.
   PubMedGoogle Scholar
• Walter M, Wiesbeck G, Bloch N, Aeschbach S, Olbrich H, Seifritz E, Dürsteler-MacFarland K. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: A pilot study. Eur Neuropsychopharmacol 2008; 18:390–393.
   PubMed Web of Science ®Google Scholar
• Curran H, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: A double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction 1999; 94(5):665–674.
   PubMed Web of Science ®Google Scholar
• De Vos J, Ufkes J, Vandenbrink W, Vanbrussel G, Wolff F, Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant. Addict Behav 1999; 24(5):707–713.
   PubMedGoogle Scholar
• Curran H, Kleckham J, Bearn J, Strang J, Wanigaratne S. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: A dose-response study. Psychopharmacology 2001; 154:153–160.
   PubMed Web of Science ®Google Scholar
• Dawe S, Gray J. Craving and drug reward: A comparison of methadone and clonidine in detoxifying opiate addicts. Drug Alcohol Depend 1995; 9:207–212.
   Google Scholar
• Fareed A, Vayalapalli S, Byrd Sellers J, Casarella J, Drexler K, Amar J, Cox J, Shaw-Lutchman T. Onsite QTc interval screening for patients in methadone maintenance treatment. J Addict Dis 2010; 29(1):15–22.
   PubMed Web of Science ®Google Scholar
• Fareed A, Musselman D, Byrd-Sellers J, Vayalapalli S, Casarella C, Drexler K, Phillips L. On-site basic health screening and brief health counseling of chronic medical conditions for veterans in methadone maintenance treatment. J Addict Med 2010, Vol. 4(3) 160–66.
   Google Scholar
• Bekinschtein P, Katche C, Slipczuk LN, Igaz LM, Cammarota M, Izquierdo I, Medina JH. mTOR signaling in the hippocampus is necessary for memory formation. Neurobiol Learn Mem 2007; 87:303–307.
   PubMed Web of Science ®Google Scholar
• Parsons RG, Gafford GM, Helmstetter FJ. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J Neurosci 2006; 26:12977–12983.
   PubMed Web of Science ®Google Scholar
• Fuchs RA, See RE. Basolateral amygdala inactivation abolishes conditioned stimulus and heroin-induced reinstatement of extinguished heroin-seeking behavior in rats. Psychopharmacology (Berl) 2002; 160:425–433.
   PubMed Web of Science ®Google Scholar
• Chen S, Ren L, Huang Z. Effects of tetrodotoxin on naloxone-precipitated withdrawal syndrome in morphine-dependent rats and mice. Chin J Pharmcol Toxicol 2001; 15:434–440.
   Google Scholar
• Popik P, Wrobel M, Bisaga A. Reinstatement of morphine conditioned reward is blocked by memantine. Neuropsychopharmacology 2006; 31(1):160–170.
   PubMedGoogle Scholar
• Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J. NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference. Brain Res Bull 2005; 64(6):493–503.
   PubMedGoogle Scholar
• Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006 Nov; 20(6):806–814.
   PubMed Web of Science ®Google Scholar
• Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Jr, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004; 13(Supplement 1):S42–S66.
   Google Scholar
• Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, Renner JA, Weiss L, Saxon AJ, Fiellin DA, The physician clinical support system-buprenorphine (PCSS-B): A novel project to expand/improve buprenorphine treatment. J Gen Intern Med 2010 May 11. [Epub ahead of print].
   PubMedGoogle Scholar
• Gordon A, Liberto J, Granda S, Salmon-Cox S, Andrée T, McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict 2008; 17:459–462.
   PubMed Web of Science ®Google Scholar